Compare Eaton Corporation plc (ETN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Incyte Corporation — how do they compare? Eaton Corporation plc trades at $459.3 (market cap $172.82B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Eaton Corporation plc is far larger — about 7× Incyte Corporation's market cap, and Eaton Corporation plc pays a 0.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ETN | INCY | |
|---|---|---|
Market Cap | $172.82B | $24.54B |
Sector | Technology | Health |
52-Week High | $459.29 | $129.93 |
52-Week Low | $315.82 | $81.61 |
Enterprise Value | $193.45B | $20.04B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $459.96, up 3.37% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating expectations of $3.07. Revenue growth continues with 2026 projections at $30.0 billion, though net profit margin is expected to compress to 12.75%. Recent news highlights Eaton's $7 million Air Force contract for quantum computing grid security and strong AI infrastructure demand.
Outlook remains positive with analyst consensus price target of $499.75 (8.6% upside) and unanimous bullish ratings (26 Buy, 0 Sell). Key risks include premium valuation (P/E 45.31) and execution challenges in meeting raised 2026 guidance. The stock's proximity to 52-week highs suggests near-term consolidation potential despite strong fundamental momentum.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
